In the Claims

Claims 1-24 (canceled)

25. (currently amended) A compound represented by C:

$$R_4$$
 R_5
 R_1
 R_5
 R_1
 R_1
 R_2
 R_2
 R_2
 R_3
 R_1
 R_2
 R_3
 R_4
 R_5

wherein

m is 0, 1, 2, or 3;

n is 0, 1, 2, or 3;

p is 1, 2, or 3;

W represents CH₂, or O [[, or NR]];

X represents S [[or O]];

Y represents CR' [[, or N]];

R represents H or alkyl;

R' represents H, alkyl, or halogen;

R₁ represents H or alkyl;

R₂ represents aryl [[, or heteroaryl]];

R₃ represents H or alkyl;

R₄ represents H or alkyl;

R₅ represents H or alkyl;

R₁ and R₄ may be connected through a covalent bond;

[[R₃ and R₄ may be connected through a covalent bond;]]

 R_4 and R_5 may be connected through a covalent bond; [[or -N(R_4)(R_5) represents 4-morpholinyl;]] and

the stereochemical configuration at a stereocenter in a compound represented by C is R, S, or a mixture thereof.

- 26. (canceled)
- 27. (canceled)
- 28. (canceled)
- 29. (original) The compound of claim 25, wherein n is 1 or 2; and p is 2.
- 30. (original) The compound of claim 25, wherein R' represents H.
- 31. (currently amended) The compound of claim 25, wherein R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, or 2-fluorophenyl [[, or 5-chlorobenzo[b]thiophen-3-yl]].
- 32. (canceled)
- 33. (canceled)
- 34. (canceled)
- 35. (currently amended) The compound of claim 25, wherein [[X represents S; Y represents CR'; W represents CH₂ or O;]] n is 1 or 2; p is 2; and R' represents H.
- 36. (currently amended) The compound of claim 25, wherein [[X represents S; Y represents CR'; W represents CH₂ or O;]] n is 1 or 2; p is 2; R' represents H; and R₂ represents phenyl, 3-chlorophenyl, 4-chlorophenyl, or 2-fluorophenyl [[, or 5-chlorobenzo[b]thiophen-3-yl]].

Claims 37-44 (canceled)

45. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.

- 46. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
- 47. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
- 48. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
- 49. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
- 50. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor or transporter.
- 51. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
- 52. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
- 53. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an IC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
- 54. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 1 μ M in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.

- 55. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 100 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
- 56. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound has an EC₅₀ less than 10 nM in an assay based on a mammalian dopamine, muscarinic or serotonin receptor.
- 57. (currently amended) The compound of claim [[1, 17,]] 25, [[or 37,]] wherein said compound is a single stereoisomer.
- 58. (currently amended) A formulation, comprising a compound of claim [[1, 17,]] 25 [[, or 37]]; and a pharmaceutically acceptable excipient.

Claims 59-105 (canceled)